Regenxbio gene-therapy shows positive long-term effect in wet AMD [Seeking Alpha]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Seeking Alpha
HealthcareRegenxbio gene-therapy shows positive long-term effect in wet AMDApr. 22, 2020 9:16 AM ET|REGENXBIO Inc. (RGNX)Douglas W. HouseREGENXBIO (NASDAQ:announcesPhase 1/2a clinical trialTwo-year data on cohort 3 showed a mean improvement in vision of 14 letters and stable retinal thickness (+2 µm). 50% (n=3/6) remain anti-VEGF injection-free. One additional participant was anti-VEGF injection-free for nine months [an example of anti-VEGF therapy is Regeneron Pharmaceuticals' Eylea (aflibercept)].73% (n=8/11) of cohort 5 remain anti-VEGF injection-free over nine months.One-year data from cohorts 4 & 5 should be available mid-year. A pivotal study should launch in H2.Click to subscribe to real-time analytics on RGNXNow read:OrganiGram down 3% premarket on $49M stock sales deal »
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a "buy" rating on the stock.MarketBeat
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an "outperform" rating on the stock.MarketBeat
- Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.MarketBeat
- Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewswire
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 11/28/25 - Form 144
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- REGN's page on the SEC website